Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Påhlman S[au]:

Hypoxia and hypoxia-inducible factors in neuroblastoma. Påhlman S et al. Cell Tissue Res. (2018)

Hypoxia, pseudohypoxia and cellular differentiation. Mohlin S et al. Exp Cell Res. (2017)

No reason to reconsider HIF-2 as an oncogene in neuroblastoma and other cancer forms. Mohlin S et al. Proc Natl Acad Sci U S A. (2017)

Search results

Items: 1 to 50 of 181

1.

ALK positively regulates MYCN activity through repression of HBP1 expression.

Claeys S, Denecker G, Durinck K, Decaesteker B, Mus LM, Loontiens S, Vanhauwaert S, Althoff K, Wigerup C, Bexell D, Dolman E, Henrich KO, Wehrmann L, Westerhout EM, Demoulin JB, Kumps C, Van Maerken T, Laureys G, Van Neste C, De Wilde B, De Wever O, Westermann F, Versteeg R, Molenaar JJ, Påhlman S, Schulte JH, De Preter K, Speleman F.

Oncogene. 2018 Dec 11. doi: 10.1038/s41388-018-0595-3. [Epub ahead of print]

PMID:
30538293
2.

Patient-Derived Xenograft Models Reveal Intratumor Heterogeneity and Temporal Stability in Neuroblastoma.

Braekeveldt N, von Stedingk K, Fransson S, Martinez-Monleon A, Lindgren D, Axelson H, Levander F, Willforss J, Hansson K, Øra I, Backman T, Börjesson A, Beckman S, Esfandyari J, Berbegall AP, Noguera R, Karlsson J, Koster J, Martinsson T, Gisselsson D, Påhlman S, Bexell D.

Cancer Res. 2018 Oct 15;78(20):5958-5969. doi: 10.1158/0008-5472.CAN-18-0527. Epub 2018 Aug 28.

PMID:
30154149
3.

Promoter-associated proteins of EPAS1 identified by enChIP-MS - A putative role of HDX as a negative regulator.

Hamidian A, Vaapil M, von Stedingk K, Fujita T, Persson CU, Eriksson P, Veerla S, De Preter K, Speleman F, Fujii H, Påhlman S, Mohlin S.

Biochem Biophys Res Commun. 2018 May 5;499(2):291-298. doi: 10.1016/j.bbrc.2018.03.150. Epub 2018 Mar 26.

PMID:
29577908
4.

A Novel Topical PPARγ Agonist Induces PPARγ Activity in Ulcerative Colitis Mucosa and Prevents and Reverses Inflammation in Induced Colitis Models.

Da Silva S, Keita ÅV, Mohlin S, Påhlman S, Theodorou V, Påhlman I, Mattson JP, Söderholm JD.

Inflamm Bowel Dis. 2018 Mar 19;24(4):792-805. doi: 10.1093/ibd/izx079.

PMID:
29529198
5.

Refined control of cell stemness allowed animal evolution in the oxic realm.

Hammarlund EU, von Stedingk K, Påhlman S.

Nat Ecol Evol. 2018 Feb;2(2):220-228. doi: 10.1038/s41559-017-0410-5. Epub 2018 Jan 18. Review.

PMID:
29348641
6.

No reason to reconsider HIF-2 as an oncogene in neuroblastoma and other cancer forms.

Mohlin S, von Stedingk K, Pietras A, Påhlman S.

Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):E10856-E10858. doi: 10.1073/pnas.1716644115. Epub 2017 Dec 12. No abstract available.

7.

Hypoxia and hypoxia-inducible factors in neuroblastoma.

Påhlman S, Mohlin S.

Cell Tissue Res. 2018 May;372(2):269-275. doi: 10.1007/s00441-017-2701-1. Epub 2017 Oct 14. Review.

8.

Neuroblastoma patient-derived xenograft cells cultured in stem-cell promoting medium retain tumorigenic and metastatic capacities but differentiate in serum.

Persson CU, von Stedingk K, Bexell D, Merselius M, Braekeveldt N, Gisselsson D, Arsenian-Henriksson M, Påhlman S, Wigerup C.

Sci Rep. 2017 Aug 31;7(1):10274. doi: 10.1038/s41598-017-09662-8.

9.

Myc-induced glutaminolysis bypasses HIF-driven glycolysis in hypoxic small cell lung carcinoma cells.

Munksgaard Thorén M, Vaapil M, Staaf J, Planck M, Johansson ME, Mohlin S, Påhlman S.

Oncotarget. 2017 Jul 25;8(30):48983-48995. doi: 10.18632/oncotarget.16904.

10.

Hypoxia, pseudohypoxia and cellular differentiation.

Mohlin S, Wigerup C, Jögi A, Påhlman S.

Exp Cell Res. 2017 Jul 15;356(2):192-196. doi: 10.1016/j.yexcr.2017.03.007. Epub 2017 Mar 8. Review.

PMID:
28284840
11.

Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers.

Allaoui R, Bergenfelz C, Mohlin S, Hagerling C, Salari K, Werb Z, Anderson RL, Ethier SP, Jirström K, Påhlman S, Bexell D, Tahin B, Johansson ME, Larsson C, Leandersson K.

Nat Commun. 2016 Oct 11;7:13050. doi: 10.1038/ncomms13050.

12.

Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort.

Tadeo I, Berbegall AP, Castel V, García-Miguel P, Callaghan R, Påhlman S, Navarro S, Noguera R.

Br J Cancer. 2016 Aug 9;115(4):480-9. doi: 10.1038/bjc.2016.210. Epub 2016 Jul 14.

13.

Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer.

Wigerup C, Påhlman S, Bexell D.

Pharmacol Ther. 2016 Aug;164:152-69. doi: 10.1016/j.pharmthera.2016.04.009. Epub 2016 Apr 29. Review.

14.

Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours.

Braekeveldt N, Wigerup C, Tadeo I, Beckman S, Sandén C, Jönsson J, Erjefält JS, Berbegall AP, Börjesson A, Backman T, Øra I, Navarro S, Noguera R, Gisselsson D, Påhlman S, Bexell D.

Cancer Lett. 2016 Jun 1;375(2):384-389. doi: 10.1016/j.canlet.2016.02.046. Epub 2016 Mar 18.

15.

HIF2α contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells.

Alam MW, Persson CU, Reinbothe S, Kazi JU, Rönnstrand L, Wigerup C, Ditzel HJ, Lykkesfeldt AE, Påhlman S, Jögi A.

Oncotarget. 2016 Mar 8;7(10):11238-50. doi: 10.18632/oncotarget.7167.

16.

PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma.

Mohlin S, Hamidian A, von Stedingk K, Bridges E, Wigerup C, Bexell D, Påhlman S.

Cancer Res. 2015 Nov 1;75(21):4617-28. doi: 10.1158/0008-5472.CAN-15-0708. Epub 2015 Oct 2.

17.

Differential HIF-1α and HIF-2α Expression in Mammary Epithelial Cells during Fat Pad Invasion, Lactation, and Involution.

Påhlman S, Lund LR, Jögi A.

PLoS One. 2015 May 8;10(5):e0125771. doi: 10.1371/journal.pone.0125771. eCollection 2015.

18.

Differential regulation of HIF-1α and HIF-2α in neuroblastoma: Estrogen-related receptor alpha (ERRα) regulates HIF2A transcription and correlates to poor outcome.

Hamidian A, von Stedingk K, Munksgaard Thorén M, Mohlin S, Påhlman S.

Biochem Biophys Res Commun. 2015 Jun 5;461(3):560-7. doi: 10.1016/j.bbrc.2015.04.083. Epub 2015 Apr 23.

19.

Individual patient risk stratification of high-risk neuroblastomas using a two-gene score suited for clinical use.

von Stedingk K, De Preter K, Vandesompele J, Noguera R, Øra I, Koster J, Versteeg R, Påhlman S, Lindgren D, Axelson H.

Int J Cancer. 2015 Aug 15;137(4):868-77. doi: 10.1002/ijc.29461. Epub 2015 Feb 20.

20.

The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.

Agarwal S, Kazi JU, Mohlin S, Påhlman S, Rönnstrand L.

Oncogene. 2015 Aug 27;34(35):4581-90. doi: 10.1038/onc.2014.383. Epub 2014 Dec 1.

PMID:
25435369
21.

TLX activates MMP-2, promotes self-renewal of tumor spheres in neuroblastoma and correlates with poor patient survival.

Chavali PL, Saini RK, Zhai Q, Vizlin-Hodzic D, Venkatabalasubramanian S, Hayashi A, Johansson E, Zeng ZJ, Mohlin S, Påhlman S, Hansford L, Kaplan DR, Funa K.

Cell Death Dis. 2014 Oct 30;5:e1502. doi: 10.1038/cddis.2014.449.

22.

Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours.

Braekeveldt N, Wigerup C, Gisselsson D, Mohlin S, Merselius M, Beckman S, Jonson T, Börjesson A, Backman T, Tadeo I, Berbegall AP, Ora I, Navarro S, Noguera R, Påhlman S, Bexell D.

Int J Cancer. 2015 Mar 1;136(5):E252-61. doi: 10.1002/ijc.29217. Epub 2014 Oct 7.

23.

Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments.

Zhang X, Fryknäs M, Hernlund E, Fayad W, De Milito A, Olofsson MH, Gogvadze V, Dang L, Påhlman S, Schughart LA, Rickardson L, D'Arcy P, Gullbo J, Nygren P, Larsson R, Linder S.

Nat Commun. 2014;5:3295. doi: 10.1038/ncomms4295.

24.

EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation.

Reinbothe S, Larsson AM, Vaapil M, Wigerup C, Sun J, Jögi A, Neumann D, Rönnstrand L, Påhlman S.

Biochem Biophys Res Commun. 2014 Feb 28;445(1):163-9. doi: 10.1016/j.bbrc.2014.01.165. Epub 2014 Feb 3.

25.

The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner.

Sun J, Mohlin S, Lundby A, Kazi JU, Hellman U, Påhlman S, Olsen JV, Rönnstrand L.

Oncogene. 2014 Nov 13;33(46):5360-9. doi: 10.1038/onc.2013.479. Epub 2013 Nov 11.

PMID:
24213578
26.

snoRNPs Regulate Telomerase Activity in Neuroblastoma and Are Associated with Poor Prognosis.

von Stedingk K, Koster J, Piqueras M, Noguera R, Navarro S, Påhlman S, Versteeg R, Ora I, Gisselsson D, Lindgren D, Axelson H.

Transl Oncol. 2013 Aug 1;6(4):447-57. Print 2013 Aug.

27.

Quantitative proteomics profiling of primary lung adenocarcinoma tumors reveals functional perturbations in tumor metabolism.

Pernemalm M, De Petris L, Branca RM, Forshed J, Kanter L, Soria JC, Girard P, Validire P, Pawitan Y, van den Oord J, Lazar V, Påhlman S, Lewensohn R, Lehtiö J.

J Proteome Res. 2013 Sep 6;12(9):3934-43. doi: 10.1021/pr4002096. Epub 2013 Aug 13.

28.

MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells.

Zirath H, Frenzel A, Oliynyk G, Segerström L, Westermark UK, Larsson K, Munksgaard Persson M, Hultenby K, Lehtiö J, Einvik C, Påhlman S, Kogner P, Jakobsson PJ, Henriksson MA.

Proc Natl Acad Sci U S A. 2013 Jun 18;110(25):10258-63. doi: 10.1073/pnas.1222404110. Epub 2013 Jun 3.

29.

The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling.

Kazi JU, Vaapil M, Agarwal S, Bracco E, Påhlman S, Rönnstrand L.

Cell Signal. 2013 Sep;25(9):1852-60. doi: 10.1016/j.cellsig.2013.05.016. Epub 2013 May 21.

PMID:
23707526
30.
31.

Hypoxic conditions induce a cancer-like phenotype in human breast epithelial cells.

Vaapil M, Helczynska K, Villadsen R, Petersen OW, Johansson E, Beckman S, Larsson C, Påhlman S, Jögi A.

PLoS One. 2012;7(9):e46543. doi: 10.1371/journal.pone.0046543. Epub 2012 Sep 28.

32.

Cancer cell differentiation heterogeneity and aggressive behavior in solid tumors.

Jögi A, Vaapil M, Johansson M, Påhlman S.

Ups J Med Sci. 2012 May;117(2):217-24. doi: 10.3109/03009734.2012.659294. Epub 2012 Feb 29. Review.

33.

Tumor-initiating cells in childhood neuroblastoma--letter.

Mohlin S, Pietras A, Wigerup C, Ora I, Andäng M, Nilsson K, Olofsson T, Gisselsson D, Påhlman S.

Cancer Res. 2012 Feb 1;72(3):821-2; author reply 823. doi: 10.1158/0008-5472.CAN-11-1761. No abstract available.

34.

HIF-2α expression is suppressed in SCLC cells, which survive in moderate and severe hypoxia when HIF-1α is repressed.

Munksgaard Persson M, Johansson ME, Monsef N, Planck M, Beckman S, Seckl MJ, Rönnstrand L, Påhlman S, Pettersson HM.

Am J Pathol. 2012 Feb;180(2):494-504. doi: 10.1016/j.ajpath.2011.10.014. Epub 2011 Nov 21.

PMID:
22115707
35.

Neuroblastoma research progress--a 2011 perspective.

Henriksson MA, Påhlman S.

Semin Cancer Biol. 2011 Oct;21(4):215-6. doi: 10.1016/j.semcancer.2011.10.003. No abstract available.

PMID:
22044552
36.

High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer.

Hjelm B, Brennan DJ, Zendehrokh N, Eberhard J, Nodin B, Gaber A, Pontén F, Johannesson H, Smaragdi K, Frantz C, Hober S, Johnson LB, Påhlman S, Jirström K, Uhlen M.

Proteomics Clin Appl. 2011 Dec;5(11-12):624-35. doi: 10.1002/prca.201100020.

PMID:
21956899
37.

Neuroblastoma aggressiveness in relation to sympathetic neuronal differentiation stage.

Mohlin SA, Wigerup C, Påhlman S.

Semin Cancer Biol. 2011 Oct;21(4):276-82. doi: 10.1016/j.semcancer.2011.09.002. Epub 2011 Sep 16. Review.

PMID:
21945591
38.

JAG2 induction in hypoxic tumor cells alters Notch signaling and enhances endothelial cell tube formation.

Pietras A, von Stedingk K, Lindgren D, Påhlman S, Axelson H.

Mol Cancer Res. 2011 May;9(5):626-36. doi: 10.1158/1541-7786.MCR-10-0508. Epub 2011 Mar 14.

39.

Prognostic value of SOX2 expression in neuroblastoma.

Gómez-Mateo Mdel C, Piqueras M, Påhlman S, Noguera R, Navarro S.

Genes Chromosomes Cancer. 2011 May;50(5):374-7. doi: 10.1002/gcc.20859. Epub 2011 Feb 8. No abstract available.

PMID:
21305642
40.

Hunting for protein markers of hypoxia by combining plasma membrane enrichment with a new approach to membrane protein analysis.

Cifani P, Bendz M, Wårell K, Hansson K, Levander F, Sandin M, Krogh M, Ovenberger M, Fredlund E, Vaapil M, Pietras A, Påhlman S, James P.

J Proteome Res. 2011 Apr 1;10(4):1645-56. doi: 10.1021/pr100982j. Epub 2011 Feb 23.

PMID:
21235201
41.

The HIF-2α-driven pseudo-hypoxic phenotype in tumor aggressiveness, differentiation, and vascularization.

Pietras A, Johnsson AS, Påhlman S.

Curr Top Microbiol Immunol. 2010;345:1-20. doi: 10.1007/82_2010_72. Review.

PMID:
20517717
42.

MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.

Lovén J, Zinin N, Wahlström T, Müller I, Brodin P, Fredlund E, Ribacke U, Pivarcsi A, Påhlman S, Henriksson M.

Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1553-8. doi: 10.1073/pnas.0913517107. Epub 2010 Jan 4.

43.

HIF-1alpha and HIF-2alpha are differentially regulated in vivo in neuroblastoma: high HIF-1alpha correlates negatively to advanced clinical stage and tumor vascularization.

Noguera R, Fredlund E, Piqueras M, Pietras A, Beckman S, Navarro S, Påhlman S.

Clin Cancer Res. 2009 Dec 1;15(23):7130-6. doi: 10.1158/1078-0432.CCR-09-0223. Epub 2009 Nov 10.

44.

HIF-2alpha maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells.

Pietras A, Hansford LM, Johnsson AS, Bridges E, Sjölund J, Gisselsson D, Rehn M, Beckman S, Noguera R, Navarro S, Cammenga J, Fredlund E, Kaplan DR, Påhlman S.

Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16805-10. doi: 10.1073/pnas.0904606106. Epub 2009 Sep 16.

45.

Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.

Jögi A, Brennan DJ, Rydén L, Magnusson K, Fernö M, Stål O, Borgquist S, Uhlen M, Landberg G, Påhlman S, Pontén F, Jirström K.

Mod Pathol. 2009 Dec;22(12):1564-74. doi: 10.1038/modpathol.2009.124. Epub 2009 Sep 4.

46.

Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer.

Larsson AM, Jirström K, Fredlund E, Nilsson S, Rydén L, Landberg G, Påhlman S.

Clin Cancer Res. 2009 Sep 1;15(17):5552-9. doi: 10.1158/1078-0432.CCR-08-3014. Epub 2009 Aug 25.

47.

HIF-1alpha induces MXI1 by alternate promoter usage in human neuroblastoma cells.

Löfstedt T, Fredlund E, Noguera R, Navarro S, Holmquist-Mengelbier L, Beckman S, Påhlman S, Axelson H.

Exp Cell Res. 2009 Jul 1;315(11):1924-36. doi: 10.1016/j.yexcr.2009.02.015. Epub 2009 Feb 27.

PMID:
19254710
48.

Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells.

Pettersson HM, Pietras A, Munksgaard Persson M, Karlsson J, Johansson L, Shoshan MC, Påhlman S.

Mol Cancer Ther. 2009 Jan;8(1):160-70. doi: 10.1158/1535-7163.MCT-08-0595.

49.

Hypoxia-mediated induction of the polyamine system provides opportunities for tumor growth inhibition by combined targeting of vascular endothelial growth factor and ornithine decarboxylase.

Svensson KJ, Welch JE, Kucharzewska P, Bengtson P, Bjurberg M, Påhlman S, Ten Dam GB, Persson L, Belting M.

Cancer Res. 2008 Nov 15;68(22):9291-301. doi: 10.1158/0008-5472.CAN-08-2340.

50.

Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer.

Helczynska K, Larsson AM, Holmquist Mengelbier L, Bridges E, Fredlund E, Borgquist S, Landberg G, Påhlman S, Jirström K.

Cancer Res. 2008 Nov 15;68(22):9212-20. doi: 10.1158/0008-5472.CAN-08-1135.

Supplemental Content

Loading ...
Support Center